NOVACYT EXPANDS DEVELOPMENT PARTNERSHIP WITH IMMUNEXPRESS

Paris, France and Camberley, UK – 8 April 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has expanded its assay development contract with Immunexpress, Inc. (Immunexpress), a U.S.-based molecular diagnostic company with the first FDA cleared host response test for suspected sepsis patients, to further support the development of rapid diagnostic assays for the detection of sepsis.

http://novacyt.com/wp-content/uploads/2019/09/03.-Immunexpress-Novacyt-PR-8-4-19-final-ENGLISH.pdf